Ethical issues in dementia by Whitehouse, Peter J.
The growing number of individuals affected by
dementia will intensify the ethical issues that
emerge in clinical practice and research. Issues early
in disease relate to genetic testing, use of medica-
tions in mildly affected persons, and diagnostic 
disclosure. Research issues relate to appropriate
informed consent processes, conflict of interests,
and research design issues, such as the use of place-
bos and the use of biological tissues. In the later
stages of disease concern about appropriate thera-
peutic goals and end-of-life care is appropriate.
esearch and clinical practice with persons affect-
ed by dementia and their families present a growing num-
ber of complex ethical issues.
1 Ethics is a general term
for exploring human values and understanding what
constitutes a good and moral life. Many approaches to
ethics are normative in that they examine what is consid-
ered right or good in a particular cultural context.Others
are more descriptive in that they examine what people
believe and how they act without reference to standards.
Research and clinical ethics in dementia are challeng-
ing because of the nature of the disease. Ethical analy-
sis, particularly in the Western world, is based on inter-
actions among rational autonomous individuals.
2
Dementia threatens the rationality and independence
of persons,
3 and raises specific concerns about quality
of life.
4
Ethical issues will become more evident in the future.
First, considerably more individuals in both developed
and developing countries will be affected by dementing
illnesses, particularly Alzheimer's disease (AD). The
revolution in molecular medicine, particularly genetics,
will continue to lead to new technologies with ensuing
ethical issues. However, the recognition that our fasci-
nation with the power of genetic technology is distract-
ing us from attending to public and environmental
health issues will hopefully grow. Revolutions in health
care systems in many countries,which are due in part to
the aging of our populations, will continue to generate
new value conflicts for physicians and other providers.
The growth of managed care in the United States is one
such example.In general,however,the recognition that
health care systems around the world are facing eco-
nomic constraints will be a major challenge and result
in ethical issues relating, for example, to rationing of
services. The frail and vulnerable elderly such as those
with dementia will be at risk for being assigned low pri-
ority in such a rationing process.
In this paper,we will first discuss some of the approach-
es of modern biomedical ethics to orient the reader 
to language and methodology. Next, we will consider
the ethical issues that emerge in research and practice
involving persons affected by dementia in a chronolog-
ical or disease-stage fashion.We will begin by consider-
ing issues early in the disease, in fact, even before 
individuals are identified as having a dementing disor-
der.Then,we will consider mid-stage ethical issues that
relate to determining competency and participation in
research and in health care. We will then attempt to
consider the later stages of dementia, in which the
patient is severely demented, and eventually becomes
terminally ill.Finally,we will conclude with a discussion
of some of the trends in research and health care that
Clinical research
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Approaches in ethics
The discipline of bioethics is only a little over 25 years
old.
5-7 The term “bioethics” was introduced into the
English language by Potter.
8 He coined the term to
highlight the need for broad exploration of the rela-
tionship between biology and human values. The use
for the term was modified and limited by the Kennedy
Institute and others to focus more specifically on the
value considerations associated with the introduction
of new medical technology.
Bioethics itself is becoming more unified and profes-
sionalized. For example, in the United States, the merg-
ing of several organizations has led to the founding of
the new American Society for Bioethics and Humanities.
As an inherently interdisciplinary field, defining the
knowledge base is challenging. Individuals approach
bioethics through philosophy, medicine, nursing, law,
empirical social sciences, anthropology, history, and
other disciplines. Appropriate standards for bioethical
consultation are being developed.
As mentioned above, ethical issues emerge when there
are conflicts in what human beings value in a particular
social context.They also relate to differences in opinion
about what constitutes a virtuous individual or a good
life.The dominant mode of ethics practice in the United
States is based on an analytical philosophical approach
and the application of principles, particularly autono-
my, beneficence, and justice.
9 In this secular approach,
ethical situations are analyzed in terms of balance
among these principles.Autonomy relates to preserving
the rights of individuals to make decisions about their
own lives. Beneficence relates to the shared responsi-
bilities we have for each other, particularly the princi-
ple of nonmaleficence,ie,doing no harm.Justice address-
es at the societal level questions of fairness in health
care decision making. Ethical decisions are seen as
weighing up these three principles to arrive at the best
course of action in a particular circumstance.
Ethical analysis based on this principled approach is help-
ful.However,there are other complementary approaches
to address biomedical ethical concerns.Discourse or com-
municative ethics
10 is perhaps less abstract and focuses on
the practical real-world struggles that individuals face car-
ing for someone with dementia. The focus is on quality
communication where the development of trust and clar-
ification of the positions of different parties in the ethical
dispute are critical. Casuistry and narrative ethics
11 focus
on the stories that are told by individuals involved in eth-
ical disputes. These approaches focus on the richness of
individual lives and their complex interactions.The focus
again is on the particulars of a certain case and less on
abstract principles.
It is also important to recognize that there are close
relationships between ethics and law. As we consider
ethical issues, we should be aware of any legal statutes
that relate to the decisions that are being considered.
However,laws often cannot be applied to ethical issues
with certainty and the moral foundation of some laws
can be questioned.
Ethical issues in early disease
Before we begin our discussion of ethical issues in per-
sons who have been labeled with a diagnosis of demen-
tia, we need to consider those without manifest disease,
ie, people with subtle degrees of intellectual impairment
who might be at risk for developing frank dementia such
as AD in the future.As we age, many of us will develop
changes in our intellectual abilities, some to the point
that they could be labeled with a term such as mild 
cognitive impairment (MCI). The history of this term 
is interesting in that the initial identification of people
who had mild impairment of thinking, particularly in
memory, was by Krall
12 when he coined the term benign
senile forgetfulness. Other terms, such as aging-associat-
ed memory impairment and aging or related cognitive
decline,have also been operationalized.MCI is the most
popular term currently.The differentiation of those who
have AD from those who have cognitive abilities at the
extreme lower range of normal aging is arbitrary and
accomplished by setting a threshold on scores on quanti-
tative assessment batteries.
Ethical issues emerge in relationship to the treatment of
people with MCI.Recognizing that many of these people
will develop dementia,but have not yet,should we begin
symptomatic treatment to try to improve even a mild
degree of memory difficulties? How should we consider
the risks and benefits of long-term treatment with agents
that might prevent the onset of AD,such as vitamin E or
nonsteroidal anti-inflammatory agents? How should we
consider the ethics of cognitive enhancement using such
a “pill” for individuals who are “normal”? 
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Other ethical issues emerge in people who are at risk
for AD. In many ways, that group includes literally
everyone who is currently alive and who lives into old
age, the period of maximum risk.The chance of getting
AD increases for all of us as we approach the age of 85;
perhaps as many as half will be affected.Moreover,it is
possible that we will all develop AD if we live long
enough.
There are some individuals for whom the risk is con-
siderably greater in younger years,ie,those who belong
to families with the autosomal dominant forms of the
disease. In families with identified mutations on chro-
mosomes 1, 14, and 21, it is now possible to offer
presymptomatic genetic testing and identify those indi-
viduals who carry the gene.These individuals can have
their knowledge of risk of having the AD gene modi-
fied by genetic testing from 50/50 to close to either 0%
or 100%. Moreover, genetic susceptibility testing with
apolipoprotein E (apo E) is a form of genetic testing
that is considered by some to apply to all of us. Those
who carry the apo E allele are more at risk for the dis-
ease than those with apo E 2 or 3. However, the risk
information in the case of susceptibility testing is not as
clear-cut as in the autosomal dominant setting. Thus,
ethical issues emerge as to how valuable information
that is less precise is to individuals who consider them-
selves at risk.Risks of psychological harm and even sui-
cide exist if bad news is given and especially if it is mis-
interpreted. Moreover, ethical issues follow genetic
testing of both the susceptibility and autosomal domi-
nant type as to who should have access to the informa-
tion. For example, should insurance companies who
might modify the costs or availability of health insur-
ance based on the results of genetic tests on individuals
be informed? 
When a person crosses over the indistinct line from
severe normal aging to mild AD, it is appropriate to
consider “applying” the diagnosis to that individual.
Diagnostic disclosure raises a number of ethical issues.
Considerable cultural variation exists as to whether
physicians and the public believe it is ethical to inform
individuals of their diagnosis and prognosis. In the
United States and Northern Europe, it is usually con-
sidered best to allow the autonomous individual access
to that information, whereas in oriental and southern
European cultures, the family is often told and the
patient is protected from the diagnosis.One major issue
not often considered in these discussions of the ethics
of disclosure is what words are used when a diagnosis is
given and how the information is actually processed by
the individual and family.Their understanding of what
is said by the physician is often different from what he
or she intended the message to be.
13
Individuals should be encouraged to develop advance
directives early in the disease. A living will is a docu-
ment describing the kinds of care that the individual
would like later in the illness when they may not be
able to make their own health care decisions. We are
beginning to explore the use of such devices concerning
decisions about research participation. In addition to a
written document, the individual with dementia should
identify the person, usually the caregiver, who will
make decisions when the patient is not able to do so,ie,
a surrogate decision-maker. How a caregiver should
make the decisions is also an ethical issue. Should a
decision be a substituted judgment
14 by attempting to
mirror the decision that the affected individual would
have likely made, or “best interest” reflecting what is
considered optimal for the patient at the time the deci-
sion needs to be made?
Mid-stage issues
In order for an advance directive to activate, the com-
munity needs to determine that the individual is no
longer competent to make decisions and that the sur-
rogate decision-maker needs to become more active.
The assessment of competency is a complicated area
for physicians.The actual decision about competency is
made by a judge. However, physicians are often asked
to provide data to inform the process. Formal neu-
ropsychological testing can be administered. However,
it is best to evaluate competency in a particular domain
by asking the patient about the actual decision to be
made or similar decisions using hypothetical vignettes.
A judgment can be made about whether the patient can
understand that a decision needs to be made and
whether he or she is considering relevant factors that
affect the decision or not.
In the mid-stages of disease,the patient may be given the
opportunity to consider participation in research.A num-
ber of ethical issues are raised in this context. Informed
consent involves providing information to an individual
and allowing them to make a decision about research
participation. Dementia affects an individual's ability to
both understand the purpose and process of research and
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to make the decision to participate or not. A variety of
national and international groups are now examining the
issue of informed consent for those who are cognitively
impaired. The National Bioethics Advisory Commission
in the United States has made certain proposals concern-
ing additional protections for mentally ill research sub-
jects that involve assessing the degree of risk and involv-
ing other national boards and patient representatives to
assist review of research procedures. Alzheimer Disease
International and The International Working for the
Harmonization of Dementia Drug Guidelines have also
issued recommendations.
14 Major issues involved in these
debates are how incompetence to make research deci-
sions should be established, how a surrogate decision-
maker should be identified, and what grounds the surro-
gate decision-maker should use to decide what kinds of
research should or should not be permitted. Another
issue relates to the monitoring process that should be in
place to insure that the informed consent process is ade-
quate and the research is conducted as approved by the
Institutional Review Board.
Another active ethical issue in research relates to con-
flict of interest when physicians may gain personally—or
their institution—based on their participation in
research, particularly therapeutic trials. Inadequately
disclosed conflicts of interest threaten to undermine the
trust that the public has that the research is being con-
ducted for the benefit of society and not for the person-
al or organizational financial betterment of researchers.
Issues also relate to the control of the information col-
lected in the research project. For example, is it ethical
for drug companies to suppress negative studies? Other
ethical issues in research design that are under active
consideration at the moment include determining when
use of a placebo is inappropriate. Research practice dic-
tates that participants should be offered standard thera-
py as an option.Donepezil has become in many people’s
minds the standard of practice for symptomatic
improvement of cognition in AD.Are we at a stage that
all studies should compare new drugs with donepezil
rather than with a placebo? Most people do not believe
that we are at this stage in the field with donepezil, but
this is a point of contention.
In many research protocols, subjects are asked to donate
tissues for analysis. For example, it is common in clinical
trials to collect a blood specimen to allow determina-
tion of genotypes, such as Apo E4.The hope is to deter-
mine whether the genotypes in any way relate to respon-
siveness to the medication. However, if the affected per-
son grants permission to obtain biological tissue, ques-
tions are raised as to how long the tissue can be stored,
whether it can be used for analysis of other disease mark-
ers, and who can have access to this information.
In addition to opportunities to participate in research,
individuals in the mid-stage of the disease are often
involved in a great variety of services in the health care
system.Managed care in the United States has changed
the financial incentives for physicians and organiza-
tions providing health services. For example, in capitat-
ed managed care,providers are at risk for excessive use
of services.Patients with dementia may be at risk of not
being granted adequate access to services in a health
care environment in which they threaten to consume
more that average resources. The ethics of managed
care has attracted considerable professional and public
attention. For example, early attempts to stop physi-
cians from sharing information about other therapeutic
options not included in the patient's plan with so-called
gag rules were judged by most to be unethical.
End-stage ethical issues
As the disease progresses, patients with dementia may
become unable to make any decisions,and,in fact,unable
to communicate with their loved ones and care providers.
They often need placement in long-term residential care
facilities. A variety of ethical issues emerges in this con-
text.
15 Many of them relate to the use of restraints,
whether they are physical or chemical. As the dementia
progresses from severe to profound, many consider it
appropriate to think of AD as a terminal disease. In this
context, ethical discussions emerge as to what kinds of
interventions are effective and appropriate in the latter
stage of the disease. Should we ever place a feeding tube
in a severely demented patient? Do antibiotics alter the
course of patients who are terminally demented and have
developed infections?
Finally, there are active discussions in some countries
concerning the role of physician-assisted suicide and
euthanasia in dementia care. In the Netherlands, a
recent report
16 explored whether it is appropriate to
allow an individual in the mild stages of dementia to
commit suicide with a physician’s assistance if this is
judged as being congruent with the patient’s concep-
tions of a good life.Quite a number of individuals in the
Netherlands have also filled out advanced directivesClinical research
166
asking doctors to kill them when they reach a certain
severity of dementia. Clearly, we need to have appro-
priate forms of health care available to patients dying
with dementia. Many hospice programs provide an
appropriate model for such care. The options for end-
of-life care should focus more on the quality of life than
prolonging life.The spiritual aspects of life increasingly
become important to many. Secular bioethics is often
not comfortable when narrower religious or broader
spiritual value issues are raised.
Future trends
Many changes are occurring in the clinical and research
environment involving patients with dementia.As men-
tioned above,we will have a larger number of individu-
als affected by dementia because of the graying of our
population. Moreover, because of population mobility,
we will be called upon to involve increasingly cultural
diverse individuals in our practices and research.
Attending to the differences in ethical belief systems in
different cultures will be even more important in the
future than it is today.In some cultures,the principle of
autonomy is not as dominant as in the United States
and Northern Europe. In general, even in these
Western countries, we are questioning whether such a
strong focus on individual rights is appropriate as we
recognize that attending to the health needs of the pub-
lic and our communities requires reconsideration of the
relationships that physicians have with individual
patients.
As our health care systems continue to evolve to better
integrated systems in which acute and long-term care
will be coordinated in a smoother continuum, a variety
of ethical issues will emerge.Many of them will have to
do with the use of integrated clinical and financial
information systems. As computers and information
systems are increasingly involved in the care of patients
with dementia, confidentiality will be an increasing
issue. Moreover, as computers begin to actually play a
role in supporting care, accountability for therapeutic
decisions may become less clear.
As the number of individuals with dementia increases
and health care resources are increasingly stressed, the
level of support given to patients with dementia will be
examined. It remains to be seen how expensive thera-
pies to treat dementia will be prioritized when, for
example, the deleterious effects of environmental pol-
lution on the health of people of all ages continue to
grow. At a personal and cultural level, dementia will
challenge us as the disease of the millennium and a par-
ticularly postmodern one at that.
2 ❏
Aspectos éticos en la demencia
El progresivo aumento de sujetos que padecen de una
demencia intensificará la discusión ética que surge desde la
práctica clínica y de la investigación. Los temas éticos al ini-
cio de la enfermedad se relacionan con pruebas genéticas,
con el empleo de medicamentos en personas levemente afec-
tadas y con la revelación del diagnóstico. Los temas éticos
vinculados a la investigación se relacionan con los procesos
para obtener el consentimiento informado,con la evaluación
de los conflictos de intereses y con los diseños de investiga-
ción, tales como el uso de placebos y el empleo de tejidos
biológicos. En etapas más avanzadas de la enfermedad los
temas éticos se refieren al análisis de los objetivos terapéuti-
cos y de los cuidados terminales del paciente.
Problèmes éthiques posés par la démence
Le nombre croissant d’individus touchés par la démence
va amplifier les questions éthiques soulevées par la pra-
tique clinique et la recherche. Les problèmes éthiques qui
se posent précocément ont trait au diagnostic génétique,au
traitement éventuel des patients atteints de détérioration
mentale légère et à la révélation du diagnostic. La
recherche est confrontée au problème du consentement
éclairé adapté au patient dément, aux problèmes des
conflits d’intérêts et des protocoles de recherche qui utili-
sent des placebos et des prélèvements biologiques sur les
patients. Aux étapes ultimes de la maladie se posent les
questions de choix thérapeutiques appropriés et de soins
de fin de vie.167
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